Nuveen Asset Management LLC Acquires 129,470 Shares of LifeMD, Inc. (NASDAQ:LFMD)

Nuveen Asset Management LLC boosted its position in LifeMD, Inc. (NASDAQ:LFMD - Free Report) by 45.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 413,501 shares of the company's stock after acquiring an additional 129,470 shares during the quarter. Nuveen Asset Management LLC owned 0.95% of LifeMD worth $2,047,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Millennium Management LLC raised its stake in LifeMD by 17.1% during the fourth quarter. Millennium Management LLC now owns 885,987 shares of the company's stock worth $4,386,000 after acquiring an additional 129,327 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of LifeMD by 17.3% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,412 shares of the company's stock valued at $235,000 after purchasing an additional 7,001 shares during the last quarter. Deutsche Bank AG increased its position in LifeMD by 7,853.2% during the 4th quarter. Deutsche Bank AG now owns 45,333 shares of the company's stock worth $224,000 after purchasing an additional 44,763 shares in the last quarter. D. E. Shaw & Co. Inc. increased its position in LifeMD by 825.6% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 158,423 shares of the company's stock worth $784,000 after purchasing an additional 141,307 shares in the last quarter. Finally, Bridgeway Capital Management LLC lifted its stake in LifeMD by 7.2% in the 4th quarter. Bridgeway Capital Management LLC now owns 269,157 shares of the company's stock valued at $1,332,000 after purchasing an additional 18,000 shares during the last quarter. 35.52% of the stock is currently owned by institutional investors and hedge funds.

LifeMD Trading Up 5.3%

LFMD traded up $0.64 during trading on Friday, reaching $12.72. 1,770,312 shares of the company's stock were exchanged, compared to its average volume of 1,008,611. LifeMD, Inc. has a one year low of $3.99 and a one year high of $13.25. The firm has a fifty day moving average price of $8.11 and a two-hundred day moving average price of $6.51. The stock has a market capitalization of $578.10 million, a PE ratio of -19.88 and a beta of 2.42.

LifeMD (NASDAQ:LFMD - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.05. The business had revenue of $65.70 million for the quarter, compared to analyst estimates of $62.47 million. Sell-side analysts expect that LifeMD, Inc. will post -0.56 earnings per share for the current year.

Analysts Set New Price Targets

LFMD has been the topic of a number of research reports. HC Wainwright reaffirmed a "buy" rating and set a $14.00 target price on shares of LifeMD in a research note on Wednesday, April 30th. Cantor Fitzgerald reissued an "overweight" rating and set a $15.00 price objective on shares of LifeMD in a report on Tuesday, March 11th. Finally, B. Riley upgraded LifeMD to a "strong-buy" rating in a research report on Tuesday, March 11th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $11.00.

Insiders Place Their Bets

In other LifeMD news, CMO Jessica Friedeman sold 30,000 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $5.66, for a total transaction of $169,800.00. Following the completion of the sale, the chief marketing officer now owns 170,000 shares of the company's stock, valued at approximately $962,200. This represents a 15.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Justin Schreiber sold 21,995 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $7.53, for a total transaction of $165,622.35. Following the completion of the transaction, the chief executive officer now owns 2,553,726 shares in the company, valued at $19,229,556.78. This trade represents a 0.85% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 126,995 shares of company stock valued at $1,036,172. 18.40% of the stock is currently owned by company insiders.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.